Brief: Edgewise Therapeutics Announces Positive Top-Line Results From Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy
02/04/2025 11:05
April 2 (Reuters) - Edgewise Therapeutics Inc EWTX.O: EDGEWISE THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 CIRRUS-HCM FOUR-WEEK TRIAL OF EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY (HCM) EDGEWISE THERAPEUTICS INC - EDG-7500 WAS GENERALLY WELL-TOLERATED EDGEWISE THERAPEUTICS INC: INITIAL DATA READ-OUT FROM PART D IS EXPECTED IN SECOND HALF OF 2025 EDGEWISE: TRIAL SHOWED CLINICALLY MEANINGFUL REDUCTIONS IN LVOT GRADIENTS IN PARTICIPANTS WITH OBSTRUCTIVE HCM EDGEWISE THERAPEUTICS INC - PHASE 3 INITIATION PLANNED FOR FIRST HALF OF 2026 Source text: ID:nPn7gBgQYa Further company coverage: EWTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending